$ZURA
Zura Bio Ltd

2024 Q2 Form 10-Q Financial Statement

#000141057824000655 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.220M $4.786M $2.840M
YoY Change 9.51% 68.52% 588.77%
% of Gross Profit
Research & Development $5.539M $3.593M $4.884M
YoY Change -80.38% -26.43% -34.88%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change
% of Gross Profit
Operating Expenses $11.76M $8.379M $7.719M
YoY Change -65.32% 8.55% 1772.04%
Operating Profit -$11.76M -$8.379M -$7.719M
YoY Change -65.32% 8.55% 1772.06%
Interest Expense $1.428M $609.0K $180.0K
YoY Change -369.43% 238.33% -67.87%
% of Operating Profit
Other Income/Expense, Net $1.430M $632.0K -$2.076M
YoY Change -1291.67% -130.44% -470.59%
Pretax Income -$10.33M -$7.747M -$9.795M
YoY Change -69.64% -20.91% -6724.51%
Income Tax
% Of Pretax Income
Net Earnings -$10.33M -$7.747M -$9.600M
YoY Change -69.62% -19.3% -6592.8%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17 -$0.02 -$2.76
Diluted Earnings Per Share -$0.17 -$0.02 -$2.76
COMMON SHARES
Basic Shares Outstanding 43.59M 43.59M 5.139M
Diluted Shares Outstanding 74.95M 46.91M 3.552M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $188.4M $89.82M $44.00M
YoY Change 67.06% 104.13% 8450.33%
Cash & Equivalents $188.4M $89.82M $44.00M
Short-Term Investments
Other Short-Term Assets $1.032M $657.0K $400.0K
YoY Change 106.4% 64.25% 26.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $189.5M $90.47M $44.39M
YoY Change 67.19% 103.84% 5203.18%
LONG-TERM ASSETS
Property, Plant & Equipment $25.00K $9.000K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $25.00K $9.000K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $189.5M $90.47M $44.39M
Total Long-Term Assets $25.00K $9.000K $0.00
Total Assets $189.5M $90.48M $44.39M
YoY Change 67.21% 103.86% -68.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $990.0K $1.485M $2.409M
YoY Change -85.96% -38.36% 1139.89%
Accrued Expenses $14.08M $13.19M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.07M $14.67M $4.993M
YoY Change -24.41% 193.89% 1251.51%
LONG-TERM LIABILITIES
Long-Term Debt $2.364M $1.596M $1.500M
YoY Change 12.57% 6.4%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.364M $1.596M $1.500M
YoY Change 12.57% 6.4% -84.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.07M $14.67M $4.993M
Total Long-Term Liabilities $2.364M $1.596M $1.500M
Total Liabilities $17.44M $16.27M $6.530M
YoY Change -20.77% 149.16% -34.08%
SHAREHOLDERS EQUITY
Retained Earnings -$121.6M -$111.2M -$41.90M
YoY Change 40.06% 165.49% 363.83%
Common Stock $6.000K $4.000K $3.000K
YoY Change 50.0% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $156.5M $61.01M $27.86M
YoY Change
Total Liabilities & Shareholders Equity $189.5M $90.48M $44.39M
YoY Change 67.21% 103.86% -68.35%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$10.33M -$7.747M -$9.600M
YoY Change -69.62% -19.3% -6592.8%
Depreciation, Depletion And Amortization $1.000K
YoY Change
Cash From Operating Activities -$6.617M -$4.982M -$3.257M
YoY Change 27.99% 52.96% 1417.57%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $7.000K
YoY Change -99.83%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$5.007M
YoY Change -99.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 105.3M 0.000 45.65M
YoY Change 31.95% -100.0% 356.53%
NET CHANGE
Cash From Operating Activities -6.617M -4.982M -3.257M
Cash From Investing Activities -10.00K -5.007M
Cash From Financing Activities 105.3M 0.000 45.65M
Net Change In Cash 98.63M -9.989M 42.40M
YoY Change 43.25% -123.56% -19854.08%
FREE CASH FLOW
Cash From Operating Activities -$6.617M -$4.982M -$3.257M
Capital Expenditures $10.00K $7.000K
Free Cash Flow -$6.627M -$4.989M
YoY Change -39.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43593678
CY2024Q1 us-gaap Cash
Cash
89817000
CY2023Q4 us-gaap Cash
Cash
99806000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
657000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1037000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
90474000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
100843000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14674000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14674000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20302000
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
1596000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
990000
CY2024Q1 us-gaap Liabilities
Liabilities
16270000
CY2023Q4 us-gaap Liabilities
Liabilities
21292000
CY2024Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
11663000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18680000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
172246000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162820000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111241000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001855644
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43593678
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43593678
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2024Q1 zura Transfers Between Level2 And Level3
TransfersBetweenLevel2AndLevel3
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-40598
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ZURA BIO LIMITED
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1725736
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1489 W. Warm Springs Road, Suite 110
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2024Q1 dei City Area Code
CityAreaCode
702
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
757-6133
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43593678
CY2024Q1 us-gaap Cash
Cash
89817000
CY2023Q4 us-gaap Cash
Cash
99806000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1037000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
90474000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
100843000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2024Q1 us-gaap Assets
Assets
90483000
CY2023Q4 us-gaap Assets
Assets
100843000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14674000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14674000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20302000
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
1596000
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent
SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
990000
CY2024Q1 us-gaap Liabilities
Liabilities
16270000
CY2023Q4 us-gaap Liabilities
Liabilities
21292000
CY2024Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
11663000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18680000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43593678
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
172246000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162820000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111241000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59330000
CY2024Q1 us-gaap Minority Interest
MinorityInterest
1541000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1541000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62550000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90483000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100843000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3593000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4884000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4786000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2835000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
8379000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7719000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8379000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7719000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1215000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
606000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-177000
CY2023Q1 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
632000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2076000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7747000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9795000
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7747000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-9795000
CY2023Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-203000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7747000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9592000
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
CY2024Q1 zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-730000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9795000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.76
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.76
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46914542
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46914542
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3551906
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3551906
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103494000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
61009000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
59330000
CY2024Q1 us-gaap Minority Interest
MinorityInterest
1541000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
1541000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62550000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90483000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100843000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3593000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4884000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4786000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2835000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
8379000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7719000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8379000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7719000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1215000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
606000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-177000
CY2023Q1 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
632000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2076000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7747000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9795000
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-7747000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-9795000
CY2023Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
-203000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7747000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9592000
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
CY2024Q1 zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-730000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9795000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.76
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46914542
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3551906
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2409000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7747000
CY2024Q1 zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62550000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60871000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2409000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7747000
CY2024Q1 zura Temporary Equity Redemption Value To Carrying Value Adjustment
TemporaryEquityRedemptionValueToCarryingValueAdjustment
7017000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
62550000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-32056000
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000.0
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
48351000
CY2023Q1 zura Stock Issued During Period Value Research And Development License Consideration Liability
StockIssuedDuringPeriodValueResearchAndDevelopmentLicenseConsiderationLiability
4488000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2001000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9592000
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27855000
CY2024Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 zura Anti Dilution Share Issuance Compensation
AntiDilutionShareIssuanceCompensation
2186000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2409000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
180000
CY2023Q1 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
606000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-177000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-380000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
213000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-607000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
455000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4982000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5007000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56683000
CY2023Q1 zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
1030000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45653000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9989000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
42396000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99806000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
CY2023Q1 zura Conversion Of Series One Convertible Preferred Shares For Ordinary Shares
ConversionOfSeriesOneConvertiblePreferredSharesForOrdinaryShares
14686000
CY2024Q1 zura Temporary Equity Redemption Value To Carrying Value Adjustment Non Cash Activities
TemporaryEquityRedemptionValueToCarryingValueAdjustmentNonCashActivities
7017000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
CY2023Q1 zura Assumption Of Public And Private Placement Warrants In Connection With Business Combination
AssumptionOfPublicAndPrivatePlacementWarrantsInConnectionWithBusinessCombination
3715000
CY2023Q1 zura Settlement Of Research And Development License Consideration Liability
SettlementOfResearchAndDevelopmentLicenseConsiderationLiability
4488000
CY2023Q1 zura Transaction Costs Include In Accounts Payable
TransactionCostsIncludeInAccountsPayable
154000
CY2023Q1 zura Reclassification Of Deferred Transaction Costs To Additional Paid In Capital
ReclassificationOfDeferredTransactionCostsToAdditionalPaidInCapital
4015000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
14686000
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
4000000.0
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
48351000
CY2023Q1 zura Stock Issued During Period Value Research And Development License Consideration Liability
StockIssuedDuringPeriodValueResearchAndDevelopmentLicenseConsiderationLiability
4488000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2001000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9592000
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
203000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27855000
CY2024Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-7747000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-9795000
CY2023Q1 zura Anti Dilution Share Issuance Compensation
AntiDilutionShareIssuanceCompensation
2186000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2409000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
180000
CY2023Q1 zura Fair Value Adjustment Of Share Based Payment Liability
FairValueAdjustmentOfShareBasedPaymentLiability
1854000
CY2023Q1 zura Fair Value Adjustment Of Note Payable
FairValueAdjustmentOfNotePayable
2244000
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
606000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-177000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-380000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
213000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-607000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
455000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4982000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3257000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
CY2024Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5000000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5007000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10000000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56683000
CY2023Q1 zura Payment Of Deferred Transaction Costs
PaymentOfDeferredTransactionCosts
1030000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45653000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9989000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
42396000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99806000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1567000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89817000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43963000
CY2023Q1 zura Conversion Of Series One Convertible Preferred Shares For Ordinary Shares
ConversionOfSeriesOneConvertiblePreferredSharesForOrdinaryShares
14686000
CY2024Q1 zura Temporary Equity Redemption Value To Carrying Value Adjustment Non Cash Activities
TemporaryEquityRedemptionValueToCarryingValueAdjustmentNonCashActivities
7017000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
CY2023Q1 zura Assumption Of Public And Private Placement Warrants In Connection With Business Combination
AssumptionOfPublicAndPrivatePlacementWarrantsInConnectionWithBusinessCombination
3715000
CY2023Q1 zura Reclassification Of Public Warrant Liability To Equity
ReclassificationOfPublicWarrantLiabilityToEquity
2001000
CY2023Q1 zura Settlement Of Research And Development License Consideration Liability
SettlementOfResearchAndDevelopmentLicenseConsiderationLiability
4488000
CY2023Q1 zura Transaction Costs Include In Accounts Payable
TransactionCostsIncludeInAccountsPayable
154000
CY2023Q1 zura Reclassification Of Deferred Transaction Costs To Additional Paid In Capital
ReclassificationOfDeferredTransactionCostsToAdditionalPaidInCapital
4015000
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23714652
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15251922
CY2024Q1 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2023Q1 zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
1900000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
990000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
606000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1596000
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
33996674
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23714652
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15251922
CY2024Q1 zura Fair Value Liability Level1 To Level2 Transfers Amount
FairValueLiabilityLevel1ToLevel2TransfersAmount
0
CY2023Q1 zura Gain Or Loss On Remeasurement Of Research And Development License Consideration Liability
GainOrLossOnRemeasurementOfResearchAndDevelopmentLicenseConsiderationLiability
1900000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
990000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
606000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1596000
CY2024Q1 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
5000000
CY2023Q4 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
10000000
CY2024Q1 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7246000
CY2023Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6091000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1485000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2749000
CY2024Q1 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
390000
CY2023Q4 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
1201000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
553000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
261000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14674000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2023 zura Percentage Of Annual Increase In Payment
PercentageOfAnnualIncreaseInPayment
0.10
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
267939
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
5000000
CY2023Q4 zura Accrued2023 Lilly License Costs
Accrued2023LillyLicenseCosts
10000000
CY2024Q1 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7246000
CY2023Q4 zura Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6091000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1485000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2749000
CY2024Q1 zura Accrued Bonus Cost Current
AccruedBonusCostCurrent
390000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
553000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
261000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
14674000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
20302000
CY2023 zura Percentage Of Annual Increase In Payment
PercentageOfAnnualIncreaseInPayment
0.10
CY2023Q1 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
267939
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 zura Exchange Ratio For Ordinary Shares Pursuant To Business Combination
ExchangeRatioForOrdinarySharesPursuantToBusinessCombination
108.083
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
33996674
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q1 zura Number Of Warrants Exercised Or Redeemed
NumberOfWarrantsExercisedOrRedeemed
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2409000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2366000
CY2024Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
11700000
CY2024Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2409000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2366000
CY2024Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
11700000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000655-index-headers.html Edgar Link pending
0001410578-24-000655-index.html Edgar Link pending
0001410578-24-000655.txt Edgar Link pending
0001410578-24-000655-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zura-20240331.xsd Edgar Link pending
zura-20240331x10q.htm Edgar Link pending
zura-20240331xex31d1.htm Edgar Link pending
zura-20240331xex31d2.htm Edgar Link pending
zura-20240331xex32d1.htm Edgar Link pending
zura-20240331xex32d2.htm Edgar Link pending
zura-20240331x10q_htm.xml Edgar Link completed
zura-20240331_def.xml Edgar Link unprocessable
zura-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
zura-20240331_cal.xml Edgar Link unprocessable
zura-20240331_pre.xml Edgar Link unprocessable